- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Real World Benefit Related to Improving Corneal Staining
Richard Adler, MD, FACS, leads a discussion on real-world signs, symptoms and patient reactions associated with the treatment for DED.
EP: 1.Navigating Unmet Needs in Dry Eye Disease Therapies
EP: 2.Key Takeaways from Phase 4 Switch Trial Presented at AAO
EP: 3.Real World Benefit Related to Improving Corneal Staining
EP: 4.Overview of Phase 3 Perfluorohexyloctane Studies at AAO 2023
EP: 5.Updates from the SAHARA Trial at AAO 2023
EP: 6.Dual Mechanism Dry Eye Treatment Shows Promise for Symptoms and Compliance
This is a video synopsis/summary of a Post Conference Perspectives featuring Richard Adler, MD.
Adler discusses why the results showing improvement in both symptoms and signs with switching from Restasis (cyclosporine ophthalmic emulsion 0.05%) to Cequa (cyclosporine ophthalmic solution 0.09%) have real-world relevance.
He notes that in practice, both patients and doctors use symptoms as an overall indicator of treatment success. Symptom relief matters greatly in determining real-world effectiveness.
As for signs, improving corneal staining is important because this directly impacts blurry vision, which is a major frustration for patients. Even after otherwise successful cataract or refractive surgery, persisting corneal staining from dry eye can cause blurred vision and patient dissatisfaction.
By demonstrating the ability to improve both symptoms and vision-blurring corneal signs in incomplete Restasis responders switched to Cequa, study results offer meaningful real-world benefits.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
